BADBIR stands for the British Association of Dermatologists Biologic and Immunomodulators Register. We are a UK and Eire observational study seeking to assess the long-term safety of biologic treatments for psoriasis. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for psoriasis should be registered with us. Once a patient has joined BADBIR, they are followed up via their dermatologist as we assess their clinical details.
There are currently over 160 hospital sites across the UK and Eire taking part in BADBIR by recruiting participants to join the Register. We have over 18,000 participants registered with us, with more than 110,000 follow-ups entered. BADBIR's current study end date is 2028. For more information, please see our study information page.
We're still open for new centres to register with us to begin recruiting participants. If your hospital is not yet approved, please contact the BADBIR office and we'll be able to advise you on the steps that need to be taken.
If your centre is already participating on the BADBIR study, you can register for a database account to access your centre's data.
We can only register patients who are currently seeing a dermatologist; please speak to your dermatologist about BADBIR to check whether you are eligible to join the study.
If you have already joined BADBIR and would like more information, please see our participants information page.